Real-world data demonstrate significant reduction in complications and reinterventions with medtronic micra leadless pacemaker

Results presented at esc 2021 show micra tps compares favorably to traditional pacemakers dublin, aug. 27, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), the global leader in medical technology, today announced new data from the micra coverage with evidence development (ced) study, the largest evaluation of leadless pacemakers to date, which showed the micra™ transcatheter pacing system (tps) was associated with a 38% reduction in reinterventions and a 31% reduction in chronic complications at 2-years compared with traditional transvenous (tv-vvi) pacemakers. the data were presented virtually today in a late-breaking trials presentation at the european society of cardiology (esc) congress 2021.
MDT Ratings Summary
MDT Quant Ranking